Latest Bacillus Calmette-Guérin Stories
- results from this trial supported entry into Company's current Phase III bladder cancer program - BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc.
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
Dutch biopharma company Crucell and the Aeras Global TB Vaccine Foundation have started a Phase I clinical trial in Kenya of the jointly developed tuberculosis vaccine candidate, AERAS-402/Crucell Ad35.
By Anonymous Professor Brigitte Gicquel is head of the Mycobacterial Genetics unit at the Pasteur Institute in Paris, France.
MELBOURNE, Australia, Aug.
BELLEVILLE, ON, Aug. 18 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc.
The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis.
The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd.
Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...
- A trick or prank.